The Novavax COVID-19 Vaccine (NVX-CoV2373) is not a 'traditional, 'old-school' vaccination product. NVX-CoV2373) is a recombinant nanoparticle product that uses prefusion protein technology with Novavax’s proprietary nanoparticle Matrix-M, as a potent adjuvant to enhance immune responses and stimulate high levels of neutralizing antibodies.

The vaccine creates an engineered baculovirus containing a gene for a modified SARS-CoV-2 spike protein. The baculovirus is then used to infect Sf9 cultured moth cells, which then produces the spike protein The spike proteins are then harvested and encapsulated into synthetic lipid nanoparticles about 50 nanometers across, each displaying up to 14 spike proteins.

In all fairness, there should be a mechanistic comparison between the difference in using whole spike engineered from baculovirus and moth cells, versus selected synthetic mRNA from spike in order to support the claim that the vaccine may be a better option.